" /> Budigalimab - CISMeF





Preferred Label : Budigalimab;

NCIt definition : A monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed cell death 1 (PD-1, PCD-1; PDCD1), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, anti-PD-1 monoclonal antibody ABBV-181 targets and binds to PD-1, thereby blocking its binding to the PD-1 ligand, programmed cell death-1 ligand 1 (PD-L1), and preventing the activation of PD-1/PD-L1 downstream signaling pathways. This may restore immune function through the activation of cytotoxic T-lymphocytes (CTLs). PD-1, a transmembrane protein in the immunoglobulin superfamily expressed on activated T-cells, negatively regulates T-cell activation and effector function when activated by its ligand; it plays an important role in tumor evasion from host immunity.;

UNII : 6VDO4TY3OO;

CAS number : 2098225-93-3; a href https://gsrs.ncats.nih.gov/ginas/app/beta/browse-substance?search 2098225-93-3 alt lien vers site G-SRS target _blank img src /img/logos/logo_g-srs.png alt Logo G-SRS /a ;

Molecule name : ABBV 181; ABBV-181;

NCI Metathesaurus CUI : CL524834;

Details


Keyword's position in hierarchy(ies) : arborescence

You can consult :


Nous contacter.
15/05/2024


[Home] [Top]

© Rouen University Hospital. Any partial or total use of this material must mention the source.